Infection Control and Disease Surveillance in Africa

By Crystal Lubbe

December 10, 2024

The topic of National borders as a critical frontline in containing deadly infections is increasingly significant for public health initiatives. The Africa CDC plays a crucial role in addressing infection prevention and control measures linked to these borders. Their approach emphasises the necessity of robust systems and collaborations that allow for effective management of health threats that cross national boundaries.

Infection Prevention and Control (IPC) Legal Framework

The Africa CDC has developed a comprehensive IPC Legal Framework aimed at strengthening infection prevention and control measures across African Union Member States. This framework incorporates six critical areas:
– Establishing national IPC programs
– Developing evidence-based guidance
– Training and educating personnel
– Conducting surveillance for healthcare-associated infections (HAIs)
– Developing systems to monitor compliance with laws
– Mandating specific staffing and infrastructure changes in hospitals.

Implementation and Support

The Africa CDC is actively assisting Member States in implementing this IPC Legal Framework through financial, technical, and collaborative support. Workshops and joint efforts with countries like Cameroon, Liberia, Malawi, and Nigeria have been conducted to review and enhance existing IPC programs and legal instruments.

Disease Surveillance and Health Security

In collaboration with the World Health Organization (WHO) and other partners, the Africa CDC has launched initiatives to strengthen disease surveillance and health security across Africa. This includes the Health Security Partnership designed to enhance integrated disease surveillance, event-based surveillance, genomic surveillance, and epidemic intelligence. Such partnerships are invaluable for swiftly detecting and addressing health security threats, especially since national borders serve as a critical frontline in containing deadly infections.

Cross-Border Disease Control

National borders are crucial in containing infections, making RISLNET vital. It harmonises labs, integrates surveillance, and boosts cross-border collaboration to combat regional health challenges.

Multi-Sectoral Collaboration

The Africa CDC promotes a multi-sectoral approach to align IPC measures with regional and international standards. This collaborative effort is crucial for effective implementation and fostering a healthier and safer environment across the continent.

In summary, the Africa CDC’s efforts in infection prevention and control, disease surveillance, and health security therefore, illustrate the vital role of National borders as a critical frontline in containing deadly infections. Their documented initiatives highlight the importance of robust legal frameworks, cross-border collaboration, and multi-sectoral approaches to effectively combat health threats.

Reference url

Recent Posts

NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation
Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...